Annals of dermatology

Korean Dermatological Association (대한피부과학회)
권호 표지
DOI QR코드

DOI QR Code

The Risk of Rosacea According to Chronic Diseases and Medications: A 5-Year Retrospective, Multi-Institutional Case-Control Study

  • Son, Jee Hee (Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University) ;
  • Chung, Bo Young (Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University) ;
  • Jung, Min Je (Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University) ;
  • Choi, Yong Won (Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University) ;
  • Kim, Hye One (Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University) ;
  • Park, Chun Wook (Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University)
  • Received : 2017.11.20
  • Accepted : 2018.07.23
  • Published : 2018.12.01
⟨ Previous Next ⟩

Abstract

Background: Rosacea is associated with chronic systemic disease. However, research is lacking in Asian countries. Objective: To evaluate the association between rosacea and cardiovascular diseases (CVDs) related systemic comorbidities, and the use of antihypertensive and antihyperlipidemic drugs in Korea. Methods: A five-year retrospective study, using hospital database, was conducted in five medical centers for five years. Totally 1,399,528 patients were evaluated. Results: The overall frequency for diagnosed rosacea was 0.18% over five years (2,536 rosacea patients). Patients with diabetes and patients with dyslipidemia were more likely to have rosacea (odd ratio [OR] 2.724, 95% confidence interval [CI] 1.295~5.730, p=0.016; OR 1.788, 95% CI 1.445~2.212, p<0.001). Patients with CVD were less likely to have rosacea (OR 0.431, 95% CI 0.244~0.760, p=0.003). Patients with ${\alpha}$-blocker prescriptions and patients with ${\beta}$-blocker prescriptions showed a tendency diagnosed with rosacea frequently (OR 1.963, 95% CI 1.200~3.212, p=0.006; OR 3.939, 95% CI 3.512~4.419, p<0.001). Patients with [beta]-hydroxy-[beta]-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and those with fibrate, were prone to have rosacea (OR 1.599, 95% CI 1.390~1.839, p<0.001; OR 1.660, 95% CI 1.056~2.609, p=0.026). As adjusted results, among the patients who took HMG-CoA reductase inhibitor without dyslipidemia, rosacea was less likely to be diagnosed (OR 0.780, 95% CI 0.620~0.982, p=0.034). Conclusion: Rosacea is associated with chronic diseases and drugs.

Keywords

Acknowledgement

Supported by : National Research Foundation of Korea (NRF), Ministry of Health & Welfare, Hallym University

References

  1. Duman N, Ersoy Evans S, Atakan N. Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol 2014;28:1165-1169. https://doi.org/10.1111/jdv.12234
  2. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol 2015;73:604-608. https://doi.org/10.1016/j.jaad.2015.07.009
  3. Rueda LJ, Motta A, Pabon JG, Barona MI, Melendez E, Orozco B, et al. Epidemiology of rosacea in Colombia. Int J Dermatol 2017;56:510-513. https://doi.org/10.1111/ijd.13491
  4. Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011;15:53-62. https://doi.org/10.1038/jidsymp.2011.6
  5. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2009;31:1000-1006.
  6. Ozbalkan Z, Efe C, Cesur M, Ertek S, Nasiroglu N, Berneis K, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010;212:377-382. https://doi.org/10.1016/j.atherosclerosis.2010.03.035
  7. Itani S, Arabi A, Harb D, Hamzeh D, Kibbi AG. High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. Int J Dermatol 2016;55:390-395. https://doi.org/10.1111/ijd.12811
  8. Merticariu A, Marinescu L, Giurcaneanu C. Rosacea and its comorbidities. J Transl Med Res 2016;21:17-23.
  9. Spoendlin J, Voegel JJ, Jick SS, Meier CR. Diabetes mellitus, antidiabetic drugs and the risk of developing rosacea. Pharmacoepidemiology and Drug Safety 2012;21:275-276.
  10. Tan J, Schofer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M. Prevalence of rosacea in the general population of Germany and Russia - the RISE study. J Eur Acad Dermatol Venereol 2016;30:428-434. https://doi.org/10.1111/jdv.13556
  11. Koo BS, Kwon HJ, Kim BC, Lee KS, Song JY. A clinical study of 133 patients with rosacea. Korean J Dermatol 1997;35:405-410.
  12. Kim TH, Hwang SM, Lee WS, Ahn SK, Choi EH. A clinical study of rosacea. Korean J Dermatol 2000;38:583-588.
  13. Kim MS, Kim BS, Koh WS, Lee SS, Seo SL, Chun DK, et al. Rosacea: clinical study of 67 cases. Ann Dermatol 2001;13:39-43. https://doi.org/10.5021/ad.2001.13.1.39
  14. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143. https://doi.org/10.1161/hc0902.104353
  15. Luebberding S, Krueger N, Kerscher M. Skin physiology in men and women: in vivo evaluation of 300 people including TEWL, SC hydration, sebum content and skin surface pH. Int J Cosmet Sci 2013;35:477-483. https://doi.org/10.1111/ics.12068
  16. BORRIE P. Rosacea with special reference to its ocular manifestations. Br J Dermatol 1953;65:458-463. https://doi.org/10.1111/j.1365-2133.1953.tb13185.x
  17. Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol 2010;49:1235-1243. https://doi.org/10.1111/j.1365-4632.2010.04579.x
  18. Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-339. https://doi.org/10.1111/j.0906-6705.2004.00208.x
  19. McKay A, Leung BP, McInnes IB , Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903-2908. https://doi.org/10.4049/jimmunol.172.5.2903
  20. Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drugs Today (Barc) 2004;40:975-990. https://doi.org/10.1358/dot.2004.40.12.872573
  21. Katsumoto M, Shingu T, Kuwashima R, Nakata A, Nomura S, Chayama K. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005;69:1547-1555. https://doi.org/10.1253/circj.69.1547
  22. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-775. https://doi.org/10.1161/01.ATV.0000068646.76823.AE
  23. Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS, et al. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int J Cardiol 2004;97:239-244. https://doi.org/10.1016/j.ijcard.2003.09.007
  24. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868. https://doi.org/10.1161/01.RES.77.5.863
  25. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-262. https://doi.org/10.1161/res.90.3.251
  26. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M, et al. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis 2009;84:43-47.
  27. Spoendlin J, Voegel J, Jick S, Meier CR. Antihypertensive drugs and the risk of incident rosacea. Br J Dermatol 2014;171:130-136. https://doi.org/10.1111/bjd.12838
  28. Powell FC. Clinical practice. Rosacea. N Eng J Med 2005;352:793-803. https://doi.org/10.1056/NEJMcp042829
  29. Natale F, Cirillo C, Granato C, Concilio C, Siciliano A, Credendino M, et al. Worsening of rosacea in patients treated with dihydropyridine calcium channel blockers: a clinical observation. Hypertens Res 2011;34:790-791. https://doi.org/10.1038/hr.2011.32
  30. Spoendlin J, Voegel JJ, Jick SS, Meier CR. Risk of rosacea in patients with diabetes using insulin or oral antidiabetic drugs. J Invest Dermatol 2013;133:2790-2793. https://doi.org/10.1038/jid.2013.225
  31. Browne D, Meeking D, Shaw K, Cummings M. Review: endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes - pathogenesis and identification. Br J Diabetes Vasc Dis 2003;3:27-34. https://doi.org/10.1177/14746514030030010401
  32. Guarrera M, Parodi A, Cipriani C, Divano C, Rebora A. Flushing in rosacea: a possible mechanism. Arch Dermatol Res 1982;272:311-316. https://doi.org/10.1007/BF00509061
  33. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Assessment of the risk of cardiovascular disease in patients with rosacea. J Am Acad Dermatol 2016;75:336-339. https://doi.org/10.1016/j.jaad.2016.02.1158
  34. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-258. https://doi.org/10.1016/S0049-3848(03)00379-7

Cited by

  1. Association between Rosacea and Cardiovascular Diseases and Related Risk Factors: A Systematic Review and Meta-Analysis vol.2020, pp.None, 2018, https://doi.org/10.1155/2020/7015249
  2. Rosacea and the cardiovascular system vol.19, pp.9, 2018, https://doi.org/10.1111/jocd.13587
  3. Association between rosacea and cardiometabolic disease: A systematic review and meta-analysis vol.83, pp.5, 2020, https://doi.org/10.1016/j.jaad.2020.04.113